Clinical Insights in Myelofibrosis: Addressing Unmet Needs & Advancing Outcomes - Episode 3
Challenges With Defining “Ruxolitinib Failure” or Suboptimal Response to Ruxolitinib in MF
Panelists discuss how they define “ruxolitinib failure” and a suboptimal response, when they consider switching from first-line ruxolitinib, and how they differentiate between myelofibrosis-induced and JAK-induced cytopenias.
- Dr Kuykendall to Dr Konala: Switching gears a bit, Dr Konala: How do you define “ruxolitinib failure?” What is a suboptimal response, in your clinical opinion?
- Dr Kuykendall: Please comment on your threshold or when you might consider switching from first-line ruxolitinib and how you differentiate myelofibrosis-induced cytopenias (anemia or thrombocytopenia) from JAK-induced cytopenias.
Related Content:
